NR4A1 and breast cancer: In recent years, CDK4/6 inhibitors have further improved the prognosis for patients with high-risk of recurrence in hormone receptor-positive BC [14], and it has also significantly improved the progression-free survival and overall survival for patients with advanced BC [15].